Understanding HS in Down Syndrome

Recent research highlights a significant link between Down syndrome (DS) and hidradenitis suppurativa (HS). This multicenter Spanish study provides crucial insights into how HS in Down syndrome manifests clinically. Patients with both conditions often experience an earlier onset of skin lesions than the general population. Understanding these specific clinical features is essential for healthcare providers to ensure early diagnosis and better management. Furthermore, the study explores the relationship between skin phenotypes and systemic health.

Clinical Profiles and Early Disease Onset

The observational study included 69 patients across 15 Spanish hospitals. Data revealed that the median age of disease onset was just 15 years. This age is notably younger than what clinicians typically see in the general HS population. Most patients received a diagnosis at a median age of 20 years, which indicates a potential diagnostic delay. While half of the cases were classified as Hurley stage I, the groin and axilla remained the most frequently affected anatomical sites. Therefore, early screening in adolescent DS patients is highly recommended.

Comorbidities and Phenotypes of HS in Down Syndrome

Researchers identified three primary clinical phenotypes: inflammatory, follicular, and mixed. Interestingly, the inflammatory phenotype showed a strong association with a higher prevalence of systemic comorbidities. These included systemic hypertension, dyslipidemia, and cardiovascular disease. Furthermore, endocrine disorders, particularly hypothyroidism, were significantly more common in this group. Consequently, clinicians should prioritize metabolic and thyroid screenings when managing HS in Down syndrome, especially in patients with inflammatory presentations.

Therapeutic Management and Feasibility

A vital finding of the study was that Down syndrome does not restrict or contraindicate standard HS treatments. Therapeutic strategies, including various medical and surgical interventions, were applied effectively across all phenotypes. Moreover, treatment patterns did not differ significantly regardless of the specific skin manifestations. This suggests that patients with DS should have access to the full spectrum of dermatological care. Consistent monitoring and a multidisciplinary approach remain the gold standard for improving outcomes in this patient group.

FAQs

What are the common symptoms of HS in individuals with Down syndrome?

Symptoms typically include painful, recurrent nodules and abscesses in skin folds, such as the axillae (armpits) and groin. In patients with Down syndrome, these symptoms often appear during early adolescence, earlier than in the general population.

Why is the inflammatory phenotype significant in these patients?

The inflammatory phenotype is often linked to a higher burden of systemic comorbidities. These include cardiovascular diseases, high blood pressure, and thyroid issues like hypothyroidism, which require a more holistic approach to patient care.

Does Down syndrome affect the choice of HS treatment?

No, the study suggests that Down syndrome does not contraindicate or limit the use of standard HS therapies. Patients can generally receive the same medical and surgical treatments as the general HS population.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Sin-Soler M et al. Clinical Features of Hidradenitis Suppurativa in Down Syndrome Patients: A Multicenter Spanish Study. J Cutan Med Surg. 2026 Jun 03. doi: 10.1177/12034754261453366. PMID: 42233244.

Lam M, Lai C, Almuhanna N, Alhusayen R. Hidradenitis suppurativa and Down syndrome: A systematic review and meta-analysis. Pediatr Dermatol. 2020;37(6):1044-1050.

Garg A, Strunk A, Midura M, Papagermanos V, Pomerantz H. Prevalence of hidradenitis suppurativa among patients with Down syndrome: a population-based cross-sectional analysis. Br J Dermatol. 2018;178(3):697-703.